Directory

Directory

Tan-Koi Wei Chuen

Assistant Professor, Centre of Regulatory Excellence

weichuen.tankoi@duke-nus.edu.sg

65161679

About

Professional

Teaching

Publications

Bio

Assistant Professor Tan-Koi Wei Chuen is Lead of Regulatory Systems Strengthening at the Duke-NUS Centre of Regulatory Excellence (CoRE). Asst. Prof Tan-Koi’s work focuses on health policy research and capacity building in biomedical innovation and regulatory science. Her portfolio includes international capacity building programmes, as well as regulatory systems strengthening projects funded by the Asian Development Bank and the Gates Foundation on vaccine and in-vitro diagnostic regulation. Prior to joining Duke-NUS Medical School, Asst. Prof Tan-Koi was Regulatory Consultant and Team Lead of the Regulatory Research and Risk Communication teams at the Singapore’s Health Sciences Authority. A pharmacist by training, Asst. Prof Tan-Koi was awarded the Singapore Health Manpower Development Plan Fellowship for Graduate Research Programme in Public Health and received her doctoral degree from the NUS Saw Swee Hock School of Public Health.

Education

Doctor of Philosophy

National University of Singapore, Singapore

Professional Appointment(s)

Regulatory Consultant and Team Lead of the Risk Communication and Regulatory Research Unit;

Health Sciences Authority, 01/2008 - 10/2019

Content Expert

Lee Kong Chian School of Medicine, Nanyang Technological University, 01/2016 - 12/2019

Lecturer

National Collaborative Prescribing Program, National University of Singapore, 01/2018 - 12/2018

Membership

Member

Pharmacy Society of Singapore, Currently Active

Voting Delegate

US Pharmacopoeia (USP), Currently Active

Teaching

Faculty member of international workshops and post-graduate education.

• ASEAN Vaccine Security and Self-Reliance (AVSSR): Vaccine Human Resource Development Program for Enhancing Vaccine Development and Deployment Capacities in ASEAN Countries

• Duke-NUS Medical School Centre of Regulatory Excellence Graduate Certificate

• Duke-NUS Medical School Masters of Translational Medicine

• NUS Yong Loo Lin School of Medicine Master of Science in Precision Health & Medicine

Publications

Regulatory factors affecting sustainable vaccine manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.

Vaccine – Chan Mei Xuan Jessalyn; Khoo Yoong Khean; Stona Anne-Claire; Joarder Taufique; de Alwis Ruklanthi; Vogel Silke; Lim John C W; Tan-Koi Wei Chuen (2025)

63 127607-N.A

Directory

Bio

Education

Doctor of Philosophy

Professional Appointment(s)

Regulatory Consultant and Team Lead of the Risk Communication and Regulatory Research Unit;

Content Expert

Lecturer

Membership

Member

Voting Delegate

Teaching

Publications

Regulatory factors affecting sustainable vaccine manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.

Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.

Regulation in the age of calamity: Changing the regulatory paradigm.

Pandemic Vaccine Development

Enhancing Vaccine Regulation for Pandemic Preparedness

Ensuring Sustainable, Locally Relevant Vaccine R&D in Resource-Limited Settings

Promoting collaboration of regulators and patients in improving drug safety and regulatory decision making.

Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.

Pharmacovigilance activities in ASEAN countries.

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.

Applications of pharmacogenomics in regulatory science: a product life cycle review.

Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.

Post-vaccination abscess requiring surgical drainage in a tertiary children's hospital in Singapore.

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?

The importance of ethnicity definitions and pharmacogenomics in ethnobridging and pharmacovigilance

A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02.

Pharmacogenetics through a public health lens: from policy to practice.

Browser not supported

Modern websites need modern browsers